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Introduction: Malignant pleural mesothelioma (MPM)
grows aggressively within the thoracic cavity and has a very
low cure rate, thus highlighting the need for identiﬁcation of
new therapeutic targets. Adrenomedullin (AM) is a multi-
functional peptide that is highly expressed in several tu-
mors and plays an important role in angiogenesis and
tumor growth after binding to its receptors, calcitonin re-
ceptor–like receptor/receptor activity–modifying protein 2
(CLR/RAMP2) and calcitonin receptor–like receptor/
receptor activity–modifying protein 3 (CLR/RAMP3).
Methods: Real time quantitative reverse transcriptase po-
lymerase chain reaction (RT-PCR) was used to assess the
steady-state levels of AM, CLR, RAMP2 and RAMP3
messenger RNA (mRNA) transcripts in normal pleural tissue
(n¼5) and MPM (n¼24). The expression of these candidates
at protein level was revealed by immunohistochemistry. We
also characterized the expression and regulation by hypoxia
of AM system in MPM cell lines and MeT-5A cells. In vitro
and in vivo studies were performed to determine the func-
tional role of AM system in MPM.
Results: In this study, real-time quantitative reverse tran-
scriptase polymerase chain reaction showed twofold to 10-
fold higher levels of AM messenger RNA in MPM tissue than
in normal pleural tissue. The MPM cell lines H2452, H2052,
and human mesothelioma cell line MSTO-211H showed a
signiﬁcant increase in expression of AM messenger RNA
under hypoxic conditions. Our results also show that AM
stimulates cell proliferation in vitro through the Raf1 proto-
oncogene, serine/threoninekinase (CRAF)/Mitogen-activatedJournal of Thoracic Oncology Vol. 11 No. 1: 94-107protein kinase kinase 1 (MEK)/Extracellular regulated
MAPKinase (ERK) pathway. Furthermore, the proliferation,
migration, and invasion of MPM cells were decreased after
treatment with anti-AM (aAM) and anti–AM receptor
antibodies, thus indicating that MPM cells are regulated by
AM. The action of AM was speciﬁc and mediated by CLR/
RAMP2 and CLR/RAMP3 receptors. In vivo, aAM and AM22–52
antagonist therapies blocked angiogenesis and induced
apoptosis in MSTO-211H xenografts, thereby resulting in
tumor regression. Histologic examination of tumors treated
with AM22–52 and aAM antibody showed evidence of disrup-
tion of tumor vasculature with depletion of vascular endo-
thelial cells and a signiﬁcant decrease in lymphatic endothelial
cells.
Conclusions: Our ﬁndings highlight the importance
of the AM pathway in growth of MPM and in neo-
vascularization by supplying and amplifying signals
that are essential for pathologic neoangiogenesis and
lymphangiogenesis.
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Human malignant mesothelioma is a tumor of meso-
thelial origin that is seenmost frequently within the lining
of the coelomic cavities. Malignant pleural mesothelioma
(MPM) is a unique form of mesothelioma, and its devel-
opment is strongly related to exposure to asbestos ﬁbers.1
However, themechanism leading to cell transformation in
MPM remains largely unknown. Although asbestos use
has decreased in many countries in recent years, the
incidence of MPM continues to increase worldwide. The
increase in cases of MPM can be explained at least
partially by the long latency period (30 to 40 years) be-
tween exposure to asbestos and tumor development.
MPM is an aggressive tumor and notoriously refractory to
treatment,2 and neither surgery nor radiotherapy alone
has resulted in increased survival rates in patients with
MPM.2 The prognosis of patients with MPM is extremely
poor despite the currently available therapies (such as
antifolate pemetrexed combined with cisplatin3), with
median survival times varying between 8 and 14 months
after diagnosis. Consequently, new therapeutic ap-
proaches to treatment of MPM are needed. Solid tumors
require angiogenesis, or the development of new blood
vessels, for the tumor to grow beyond a minimum size.4
Moreover, many studies have indicated that mesotheli-
oma is a highly angiogenic tumor.5–10 Thus, the potential
efﬁcacy of antiangiogenic therapy for this malignancy,
which either shows no response to conventional chemo-
therapy or rapidly acquires resistance to current treat-
ments, could be particularly high.
Paracrine and autocrine mechanisms occur in many
tumors that simultaneously produce growth factors and
express the cognate receptors of these growth factors.
Mechanisms such as these are appealing targets in the
treatment of many neoplastic diseases.11 The adreno-
medullin (AM) gene, ADM, is expressed in a wide variety
of cell types, including endothelial cells and bone marrow
stromal cells, as well as in a variety of tumor cell
lines.12–14 AM is a multifunctional peptide with many
properties ranging from the ability to induce vasodilation
to the ability to regulate cellular growth and angiogen-
esis.12,15,16 AM binds to and mediates its activity through
the G protein–coupled receptor calcitonin receptor–like
receptor (CLR), with speciﬁcity for AM signaling being
conferred by receptor activity–modifying protein 2
(RAMP2) and receptor activity–modifying protein 3(RAMP3).17 The ability of CLR/RAMP2 and CLR/RAMP3
to respond with high afﬁnity to AM implies the existence
of two molecularly distinct AM receptors (AMRs), which
are referred to as AMR1 and AMR2 receptors.
18
In addition to their physiological roles, AM and its re-
ceptors have been implicated in the pathogenesis of a
variety of malignancies. AM is overexpressed in a variety
of tumor types,19 and increased expression of AM is
associated with disease progression and shortened sur-
vival in some patients with cancer.14,20,21 Moreover, AM
stimulates proliferation and inhibits apoptosis in a variety
of cell types,15,22–24 including malignant cells from
different tumors.14,20,25–27 AM also promotes the migra-
tion and invasiveness of certain carcinoma cell
lines.14,20,25 In addition to its effects on malignant cells,
AM may promote tumor growth through its ability to
promote angiogenesis and lymphangiogenesis.25–30
Consistent with this hypothesis, receptor inhibition by
the antagonistic peptide AM22–52,
31 AM receptor inter-
ference,32 or neutralizing antibodies against AM (aAM) or
its receptors reduces the proliferation and invasiveness of
tumor-derived cell lines in vitro and reduces the vascu-
larization and growth of experimental tumors in vivo.26,27
Targeting the AM/AM receptor pathway could be a
rational therapeutic approach for treatment of MPM.
Because the expression and function of the AM system in
MPM has not been well characterized, we evaluated the
expression and role of the AM/AM receptor pathway in
MPM. Accordingly, the aim of our study was to investi-
gate expression of the AM system (AM and its receptors)
and its potential role in the growth of MPM cell lines
in vitro and MPM xenografts in vivo.
Materials and methods
Human MPM tissues
We compared specimens of human pleural tissue
from patients with MPM (n ¼ 24) who were treated at
Assistance Publique Hopitaux de Marseille (AP-HM)
(Marseille, France) with specimens of normal pleural
tissue (n ¼ 5). Fresh frozen and parafﬁn-embedded tu-
mor specimens were collected from consenting patients,
assigned a deidentifying number, and provided by the
AP-HM Tumor Tissue Bank (AC-2013-1786) in accor-
dance with a protocol approved by the relevant institu-
tional committees (AP-HM/Aix-Marseille University).
Sections of parafﬁn-embedded samples (4 mm thick)
were analyzed for the presence of AM, CLR, RAMP2, and
RAMP3 proteins as previously described,20 and the
proteins’ expression was quantiﬁed by visual inspection
by an experienced pathologist. anti-AM and anti-CLR
antibodies were used at dilutions of 1/2000, whereas
anti-RAMP2 antibody was used at a dilution of 1/750,
and anti-RAMP3 antibody was used at a dilution of 1/
1500. As a control for immunostaining, antibodies that
96 Greillier et al Journal of Thoracic Oncology Vol. 11 No. 1had been preabsorbed by human synthetic AM peptide
(50 mM; Bachem, Switzerland), CLR, RAMP2 and RAMP3
peptides (50 mM, CROPS laboratory) were used instead
of primary antibodies.
Cell lines and hypoxic treatment
The cell lines H2452 and H2052 (epithelial me-
sothelioma), MSTO-211H (biphasic mesothelioma),
and MeT-5A (epithelial virus transformed, obtained
from mesothelium of noncancerous individuals) were
procured from the American Type Culture Collection
(Rockville, MD). H2452, H2052, and MSTO-211H cells
were cultured in RPMI-1640 (Roswell Park Memorial
Institute-1640) medium supplemented with 10%
heat-inactivated fetal bovine serum. Met-5A cells
were grown in deﬁned medium (M199) as recom-
mended by the American Type Culture Collection.
Cells were cultured at 37C in 20% O2 and 5% CO2
for normoxic conditions. Induction of hypoxia was
achieved by using the hypoxia mimetic 260 mM des-
ferrioxamine mesylate (DFX) (Sigma, Paris, France).
MPM and MeT-5A cells were grown to 70% conﬂu-
ence. The medium was changed, and the cells were
incubated with new medium containing 260 mM DFX
for 24 and 48 hours.
RNA preparation and real-time quantitative
reverse transcriptase-polymerase chain reaction
Before preparation of the RNA, a cryostat section was
taken from each specimen to conﬁrm the presence of
tumor tissue. Total RNA was prepared from fresh frozen
biopsy samples of MPM tumors (n ¼ 24), normal pleural
tissue (n ¼ 5), and H2452, H2052, MSTO-211H, and
MeT-5A cells; it was then reverse transcribed to cDNA as
described previously.33 Human AM, CLR, RAMP2,
RAMP3, and glyceraldehyde-3-phosphate degydrogenase
(GAPDH) messenger RNAs (mRNAs) were ampliﬁed,
detected, and quantiﬁed in real time by using an LC 480
polymerase chain reaction (PCR) system (Roche Di-
agnostics, Meylan, France) as described previously.20,33
In vitro capillary tube formation on Matrigel
The morphogenesis assay on Matrigel was performed
as described previously.12 Human umbilical vein endo-
thelial cells (HUVECs) maintained in EBM2 medium with
supplement were washed twice with phosphate-buffered
saline (PBS), trypsinized, and plated (4  104 cells) in
wells coated with growth factor–depleted Matrigel
(7mg/mL; Becton Dickinson, Paris, France) in normoxia
or hypoxia medium of H2452 or MSTO-211H with 0.5%
fetal bovine serum alone or in presence of anti-AM
(aAM) and anti-AMR (aAMR) antibodies. After 2 or 4
hours, the plates were photographed and the extent of
tube formation was assessed qualitatively.Western blot analysis
Cell extracts were prepared and immunoblotted for
phospho-Raf1 proto-oncogene, serine/threonine kinase
(pCRAF), phospho-mitogen-activated protein kinase ki-
nase1 (pMEK1), phospho extracellular regulated MAPKi-
nase (pERK1/2), and extracellular regulated MAPKinase
(ERK1/2) using the mitogen-activated protein kinase
(MAPK)-phospho-ERK1/2 pathway sampler kit (Cell
Signaling Technology Inc.) as described previously.28
Phospho-p38 was detected with monoclonal antibody
(Cell Signaling Technology Inc.). Antibody signals were
revealed by using an enhanced chemiluminescence kit
(ECL Kit, Invitrogen Life Technologies Inc.).
Cell proliferation assay
The effects of AM (10–7 M), AM22–52 (10
–6 M), rabbit
antihuman aAM (70 mg/mL), and antihuman AMR
(aCLR, aRAMP2, and aRAMP3; 70 mg/mL)-neutralizing
antibodies (puriﬁed immunoglobulin G [IgG]), which
were previously developed in house,12,26 on cell prolif-
eration were examined by cell counting (Z1 Series
Coulter Counter, Beckman Coulter Inc., Fullerton, CA).
Cell migration and invasion assays
A modiﬁed Boyden chamber assay was used to
analyze migration and chemoinvasion of H2452 and
MSTO-211H cells as described previously.12,20,34
Animal experiments
Athymic naval medical research institute (NMRI; nu/
nu) nude mice (Harlan Laboratories SARL, France) were
purchased at 5 weeks of age. Suspensions of MSTO-211H
cells (2  106 in 100 mL PBS) were injected subcutane-
ously into the right ﬂank of male mice (n ¼ 30). Tumor
sizes were determined by dial caliper measurements, and
tumor volumes were calculated with the equation for an
ellipsoid form: width  length  height  0.5236. Mice
with subcutaneous (SC) tumors larger than 1.5 cm in
diameter were humanely killed in accordance with
Aix-Marseille University Animal Rights Committee
guidelines. When the tumors reached 250 ± 50 mm3, the
animals were randomly divided into two groups. One
group (n ¼ 10) received an intraperitoneal (IP) injection
of aAM (12 mg/kg puriﬁed IgG in 200 mL PBS) every 3
days, and the second group (n¼ 10) received 50 mg of the
AM antagonist AM22–52 daily as described previously.
31
aAM antibody was characterized as described previ-
ously,28 and all IgG preparations were tested for endo-
toxin using the Pyrogent Plus Limilus Amebocyte Lysate
kit (Lonza). All antibody preparations used in our animal
studies contained less than 1.25 U/mL endotoxin. A con-
trol group (n¼ 10) received an irrelevant antibody (IgG of
the same isotype). Tumor sizes were measured every 3
days, and the mice were humanely killed 7 weeks after
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gen or embedded in parafﬁn for pathologic analysis and
immunohistochemistry.
Immunohistochemical staining
Sections (6 mm thick) were cut from formalin-ﬁxed
parafﬁn-embedded MSTO-211H xenografts. Immunohis-
tochemistry was performed using the Vectastatin Elite
ABC Universal kit (Vector Laboratories, Burlingame, CA)
as described previously.20,28 Antibodies recognizing
CD31 (1:20, Dianova), Ki67 nuclear antigen (1:100;
Dako), cleaved caspase-3 (1:100; BD Pharmingen), and
lymphatic vessel hyaluronic acid receptor-1 (LYVE-1)
(1:100) were used for our analysis. For each marker,
whole-surface staining was quantiﬁed using CALOPIX
Software (TRIBVIN Medical, Châtillon, France).
Statistical analysis
Data are expressed as the means ± standard error of
the mean (SEM) from at least three independent exper-
iments. One-way analysis of variance or Fisher’s partial
least squares difference test (Statview 512; Brain Power
Inc., Calabasas, CA) was used for statistical analysis.
Differences were considered signiﬁcant at values of
p < 0.05.
Results
Expression of AM, CLR, RAMP2, and RAMP3
mRNAs in human MPM
Total RNA from normal pleural tissue (n ¼ 5) and
MPM (n ¼ 24) was prepared to assess the steady-state
levels of AM, CLR, RAMP2, and RAMP3 mRNA tran-
scripts. The individual patterns of expression of AM
mRNA are presented in Fig. 1A. Quantiﬁcation of the AM
mRNA transcripts revealed twofold to 10-fold higher
levels of AM mRNA in MPM tissue (z20 to 110 fg/pg
GAPDH mRNA) than in normal pleural tissue (z10 fg/
pg GAPDH mRNA). Among the MPM samples, the indi-
vidual pattern of expression for AM, CLR, RAMP2, and
RAMP3 mRNAs was highly variable (see Fig. 1A). MPM
tissues also showed levels of expression of CLR mRNA
ranging between 0.01 and 0.06 fg/pg GAPDH mRNA,
RAMP2 mRNA levels between 0.1 and 1.9 fg/pg GAPDH
mRNA, and RAMP3 mRNA levels between 0.01 to 0.5 fg/
pg GAPDH mRNA, compared with mRNAs levels be-
tween 0.0078 and 0.012 fg/pg GAPDH mRNA, between
0.075 and 0.144 fg/pg GAPDH mRNA, and between
0.005 and 0.01fg/pg GAPDH mRNA in normal pleura
tissue for CLR, RAMP2, and RAMP3, respectively (see
Fig. 1A). Omission of reverse transcriptase eliminated all
signals, thus suggesting that our results were not
attributable to contaminating genomic DNA (data not
shown).Immunohistochemistry of AM, CLR, RAMP2, and
RAMP3 proteins in human MPM
Sections of epithelial MPM were labeled with anti-
bodies revealing AM, CLR, RAMP2, and RAMP3 proteins
(Fig. 1B). MPM cells displayed overt and strong labeling
for AM, CLR, RAMP2, and RAMP3 (see Fig. 1B). Illustrating
the complexity of their localization, the immunostaining
revealed strong cytoplasmic and nuclear staining for AM,
CLR, and RAMP2 in epithelial mesothelioma (see Fig. 1B,
red arrows). The same localization for AM was recently
reported in serial sections of lung cancer biopsy samples
and prostate cancer specimens.28 Numerous clusters of
labeled stromal cells with weaker labeling for AM, CLR,
and RAMP2 could be observed dispersed among the
stromal collagen septa, thus suggesting that AM system is
potentially involved in tumor–stroma cross talk (see
Fig. 1B; blue arrows). Positive AM, CLR, RAMP2, and
RAMP3 staining was completely abolished when
antibodies were preabsorbed with 50 mmol/L synthetic
AM, CLR, RAMP2, and RAMP3 peptides (data not shown).
Expression of AM and AM receptors in MPM cells
The expression of AM and AM receptors in MPM
suggests that the AM system plays a role in promoting
tumor growth in situ. Accordingly, we used H2452,
H2052, MSTO-211H, and MeT-5A cells to gain insight into
the role of the AM system in MPM cells. The presence and
cellular localization of AM and AM receptors in cell lines
under normoxic conditions were analyzed using immu-
noﬂuorescence. Representative images are shown in
Fig. 2A; in the images H2452 and MSTO-211H cells have
been immunostained for AM, CLR, RAMP2, and RAMP3
(results concerning H2052 and MeT-5A cells are shown
in Supplementary Fig. 1A). Under normoxic conditions,
AM, CLR, and RAMP2 staining generally localized to the
cytoplasm, except in H2452 cells, in which AM staining
localized to the nucleus (Fig. 2A).
Regulation of AM expression by hypoxia
Quantitative reverse transcriptase PCR (RT-PCR)
analysis demonstrated that H2452 and MSTO-211H cells
express AM mRNA (Fig. 2B). Under hypoxic conditions,
the levels of AM mRNA increased threefold to fourfold in
H2452 cells (Fig. 2B), twofold to 2.5-fold in MSTO-211H
cells (Fig. 2B), and threefold to ﬁvefold in H2052 cells
(Supplementary Fig. 1B) as early as after 24 hours. The
MeT-5A cells showed a sevenfold increase of AM mRNA
levels only after 48 hours of incubation with hypoxia
medium (see Supplementary Fig. 1B). To determine
whether the induction of AM mRNA was accompanied by
an increase in production of AM protein, the presence
and cellular localization of AM in tumor cell lines under
normoxic or hypoxic conditions was determined by
immunoﬂuorescence. A representative image is shown in
Figure 1. Expression of adrenomedullin (AM) and its receptors in human malignant pleural mesothelioma (MPM). (A)
Expression of AM and its receptors (calcitonin receptor–like receptor [CLR], receptor activity–modifying protein 2 [RAMP2],
and receptor activity–modifying protein 3 [RAMP3]) mRNAs in normal pleura and MPM tissues. Total RNA (1 mg, DNA-free)
prepared from normal pleural tissue (n ¼ 5) and MPM tissue (n ¼ 24) was transcribed into cDNA and subjected to real-
time quantitative reverse transcriptase-polymerase chain reaction for the estimation of the relative ratios of AM, CLR,
RAMP2, and RAMP3 mRNAs to glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNA as described in Materials and
Methods. Each bar depicts the mean ± standard error of the mean of two independent experiments from two independent
preparations of total RNA from MPM tissues. (B) Immunohistochemistry for AM, CLR, RAMP2, and RAMP3 in epithelial MPM.
Strong cytoplasmic and nuclear staining for AM, CLR, RAMP2, and RAMP3 is observed in MPM cells (red arrows). Stroma cells
with weaker cytoplasmic staining are also observed (blue arrows).
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Figure 2. Expression and regulation of adrenomedullin (AM) signaling in malignant pleural mesothelioma (MPM) cells. (A)
Expression of AM and its receptors in MPM cells. Immunoﬂuorescence of H2452 and MSTO-211H cells stained with antibodies
against AM, calcitonin receptor–like receptor, receptor activity–modifying protein 2, and receptor activity–modifying protein
3 revealed that except in H2452 cells (which demonstrated nuclear localization for AM), these proteins localized to the
cytoplasm. (B) Hypoxia induces the expression of AM in MPM cells. Total RNA (1 mg, DNA-free) prepared from H2452 and MSTO-
211H cells under normoxic and hypoxic conditions were reverse transcribed into cDNA and subjected to quantitative reverse
transcriptase polymerase chain reaction for the estimation of the relative AM mRNA. Each bar represents the mean ±
standard error of the mean of three independent experiments from three independent preparations of total RNA. Signiﬁcant
differences in the expression of AM in desferrioxamine mesylate (DFX)-treated cells with respect to untreated controls were
determined by a one-way analysis of variance test (***p < 0.001). (C) Cells were grown on glass slides and then incubated
under normoxic conditions or treated with 260 mM DFX for 24 hours, after which the cells were immunostained for AM (green
ﬂuorescence). Identical microscope settings and exposure times were used for the images obtained for normoxic and DFX-
treated cells to compare the expression levels under both conditions. AM was markedly overexpressed after 24 hours of
DFX treatment. (D) Morphogenic activity of hypoxia medium. Human umbilical vein endothelial cells (4  104 cells/well) were
seeded into Matrigel-precoated wells and cultured in low-serum conditions (0.5% fetal calf serum) in normoxia MSTO-211H
medium for 24 hours (a), in hypoxia MSTO-211H medium alone for 24 hours (b), or in presence of 20 mg/mL anti-AM (c) or
20 mg/mL anti–AM receptor (d) antibodies. Photographs were taken 4 hours later.
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have been immunostained for AM (green ﬂuorescence)
using highly diluted anti-AM antibody (1/5000). At thisdilution, the immunoreactive AM was barely detectable
in the cytoplasm and nucleus of the cells under normoxic
conditions (see Fig. 2C). After 24 hours of exposure to
Figure 3. Effect of adrenomedullin (AM) and AM signaling blockade on growth, migration, and invasion of mesothelioma cells
in vitro. (A) For the proliferation assays, cells were seeded at a density of 2  103 cells per well in 24 multiwell plates in
the presence of medium containing 2% fetal bovine serum. AM (10–7 M), anti-AM antibody (aAM) (70 mg/mL), anti–AM receptor
antibody (aAMR) (70 mg/mL), AM22–52 peptide (10
–6 M), or control immunoglobulin G (70 mg/mL) was added to the cells for 6
days of treatment. For each treatment, six wells were prepared for 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT) analysis. Each bar represents the mean ± standard error of the mean of three independent experiments.
Signiﬁcant differences between the growth of cells treated with aAM, aAMR, and AM22–52 and that of untreated controls were
determined by a one-way analysis of variance test (*p < 0.05; **p < 0.01; ***p < 0.001). (B and C), AM regulates MPM cell
migration and invasion. The bottom wells of all chambers were ﬁlled with RPMI-1640 (Roswell Park Memorial Institute-1640)
medium containing 2% fetal bovine serum in the presence of control buffer (control), AM (10–7 M), or endothelial growth
factor (10–7 M). MSTO-211H cells (B, 5  104 cells) or H2452 cells (C, 2  104 cells) pretreated for 30 minutes with aAM (70 mg/
mL), aCLR (23 mg/mL), anti–receptor activity–modifying protein-2 (23 mg/mL), anti–receptor activity–modifying protein-3 (23
mg/mL, aAMR), or control immunoglobulin G (70 mg/mL) were placed in the upper chamber and incubated for 4 hours with
MSTO-211H cells (B) or 16 hours with H2452 cells (C) at 37C. The cells that migrated were stained with 4’,6’-diamidino-2-
phenylindole and counted at 50 magniﬁcation using a microscope. Data are expressed as the number of migrated cells in 10
high-power ﬁelds, and the values represent the mean ± standard error of the mean of three independent experiments, each
performed in triplicate. Signiﬁcant differences in the number of treated cells with respect to untreated controls were
detected by a one-way analysis of variance test and were observed in the two cell lines. The asterisk (*) is used for com-
parison to control cells (*p < 0.05; **p < 0.01; ***p < 0.001) and the plus symbol (þ) is used in comparison to AM-treated cells
(þþp < 0.01; þþþp < 0.001).
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in AM staining in the cytoplasm and nucleus (see Fig. 2C),
which is consistentwith the up-regulation of AM synthesis
under hypoxic conditions. The production and secretion
of AM by hypoxic cells may have an angiogenic effect by
promoting a stable and functional vascular network
necessary for tumor growth in vivo. To strengthen our
ﬁndings, we explored the ability of AM secreted by MSTO-
211H and H2452 cells to induce angiogenesis and tested
this hypothesis in an in vitro Matrigel assay. Because AM
receptors are expressed in cultured primary HUVECs,12
the latter might respond to AM secreted by MSTO-211H
and H2452 cells under hypoxia to accelerate the forma-
tion of vascular structures. The addition of mediumsecreted by MSTO-211H cells cultured under hypoxia
for 24 hours resulted in a marked increase in morpho-
genesis in vitro compared with that observed after 24
hours in a normoxia medium (Fig. 2D, a and b); the
observed morphogenesis was characterized by cell elon-
gation and branching to form a network of capillary-like
structures. This effect was inhibited by function-
blocking antibodies to AM and AM receptors (see
Fig. 2D, c and d). The same data were obtained with
HUVECs incubated with the hypoxia medium of H2452
cells for 24 hours (Supplementary Fig. S2). These data
strongly suggest that AM is one of the MPM cell–derived
factors secreted under hypoxia that are responsible for
inducing angiogenesis in vivo.
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proliferation
The expression of AM and its receptors in MPM tissues
and in cell lines suggests that AM may be involved in
MPM cell growth through an autocrine/paracrine growth
loop. Of the three lines of MPM cells (MSTO-211H, H2452,
and H2052), the MSTO-211H cells showed an approxi-
mately 20% increase in proliferation in the presence of
the maximum AM concentrations (10–7 M) when
compared with untreated cells after 6 days of treatment
(Fig. 3A). Consistent with an autocrine function for AM in
these cells, aAM- or aAMR-neutralizing antibodies added
to MSTO-211H, H2452, and H2052 cell culture medium
signiﬁcantly reduced cell proliferation by as much as 40%
for MSTO-211H cells (p< 0.01), 30% for H2452 cells (p<
0.01), and 30% to 40% for H2052 cells (p < 0.01; p <
0.001) when compared with cells treated with a nonspe-
ciﬁc, isotype control antibody (see Fig. 3A). MeT-5A cells
demonstrated a lower but signiﬁcant decrease in prolif-
erationwhen incubatedwith aAM and aAMR antibodies (p
< 0.05) (see Fig. 3A). AM22–52 reduced proliferation by up
to 35% in MSTO-211H cells, whereas treatment with
AM22–52 had no effect on H2452, H2052, and MeT-5A cell
proliferation (see Fig. 3A). Taken together, these obser-
vations indicate that AM is involved in the cell growth,
notably in the three MPM cell lines, through AMR1 and
AMR2.AM induces MPM cell migration and invasion
in vitro
To determine whether AM could affect MPM cell
motility, MSTO-211H and H2452 cells were incubated
for 4 and 16 hours, respectively, in a Boyden chamber
assay in the presence of AM. The number of cells that
migrated to the lower surface of the transwell apparatus
was assessed under different conditions (Figs. 3B and C).
In the presence of AM (10–7 M), no signiﬁcant stimula-
tion was observed in MSTO-211H (see Fig. 3B), whereas
a highly signiﬁcant increase in migration was observed
for H2452 cells (p < 0.01) (see Fig. 3C). Addition of AM
(10–7 M) showed no signiﬁcant stimulation of invasion of
H2452 and MSTO-211H cells (see Figs. 3B and C). Pre-
incubation of either MSTO-211H or H2452 cells with a
combination of aCLR, aRAMP2, and aRAMP3 or aAM for
30 minutes inhibited the migration of H2452 cells but
not MSTO-211H cells (see Figs. 3B and C). However,
invasion was completely impaired for both cell types
(see Figs. 3B and C), indicating that AM promotes cell
invasion through AMR1 and AMR2. Taken together, our
data demonstrate the presence of an autocrine loop that
involves AM receptors and secreted AM, which supports
the migration and invasion of MPM cells (see Figs. 3B
and C). The addition of preimmune control IgG at70 mg/mL did not affect the stimulatory action of AM on
the MPM cell lines (see Figs. 3B and C). Treatment with
endothelial growth factor was used as positive control.AM mediates the phosphorylation of MAPK
ERK and serine/threonine protein kinase (Akt)
regulate cell proliferation, and both of these signaling
pathways function downstream of the AM/cyclic aden-
osine monophosphate pathway.35,36 Therefore, we
examined the kinetics through which AM enhanced
MAPK signaling. Treatment of MSTO-211H cells and
H2452 cells with AM led to prolonged phosphorylation
of both CRAF and MEK that was initially observed after 5
minutes of treatment and continued to increase through
120 minutes of treatment (Figs. 4A and B). Of note, the
activation of MEK by AM was more apparent in H2452
cells than in MSTO-211H cells, in which a very high
constitutive activation of MEK occurred. These increases
in signaling correlated with the sustained phosphoryla-
tion of ERK1/2 MAPK in MSTO-211H and H2452 cells
(see Figs. 4A and B), as well as in H2052 cells
(Supplementary Fig. 3). Levels of pCRAF in H2452 cells
declined more rapidly after 20 minutes of treatment (see
Fig. 4B). Inhibition of MEK, an immediate upstream
activator of ERK1/2, with U0126 (10 mM for 30 minutes)
prevented AM-mediated activation of ERK1/2 (see
Figs. 4A and B and Supplementary Fig. S3). No induction
of pERK1/2 by AM could be observed in MeT-5A cells
(see Supplementary Fig. S3). Preincubation of H2452
and MSTO-211H cells with aAM, aAMR, aCLR, aRAMP2,
aRAMP3, aCLR/aRAMP2, and aCLR/aRAMP3 decreased
the stimulatory effect of AM on pERK1/2 (see Figs. 4A
and B). Although a greater decrease was observed with
aCLR/aRAMP3, it seems that both complexes, aCLR/
aRAMP2 (AMR1) and aCLR/aRAMP3 (AMR2), are
involved in the signaling activated by AM in MPM cells
(see Figs. 4A and B). Treatment with AM had a strong
effect on the phosphorylation of p38, which peaked at 5
minutes and declined at 30 minutes in MSTO-211H cells
(see Fig. 4A) and at 1 hour in H2452 cells (see Fig. 4B).
These data suggest that AM enhances and prolongs acti-
vation of the MAPK pathway through AMR1 and AMR2.AM blockade inhibits the growth of MSTO-211H
tumor xenografts in vivo
To assess the expression and source of immunore-
active AM (ir-AM) in nude mice xenografted with SC
MSTO-211H cells, tissue sections (5 mm) were prepared
from SC xenografts, brain, and kidney from the same
nude mice and immunostained for ir-AM. The results
showed a high level of expression of ir-AM in MSTO-
211H xenografts but no expression in brain and kidney
(Fig. 5A), thus suggesting that the xenografts were the
Figure 4. Intracellular signaling pathway induced by adrenomedullin (AM) in malignant pleural mesothelioma (MPM) cells.
MSTO-211H cells (A) and H2452 cells (B) were treated with AM (10–7 M) for the indicated amounts of time and then immu-
noblotted for phospho-CRAF, CRAF, pMEK1/2, pERK1/2, ERK1/2, and pP38. MEK inhibitor (U0126) inhibited AM-induced
phosphorylation of ERK (10 mmol/L, 30 minutes). Endothelial growth factor was used as a positive control to stimulate the
phosphorylation of CRAF, MEK1/2, and ERK1/2, and P38. Preincubation of H2452 and MSTO-211H cells with anti-AM, anti–AM
receptor, anti–calcitonin receptor–like receptor (aCLR), anti–receptor activity–modifying protein 2 (aRAMP2), anti–
receptor activity–modifying protein 3 (aRAMP3), aCLR/aRAMP2, or aCLR/aRAMP3 for 30 minutes decreased AM-induced
phosphorylation of ERK1/2. b-Actin was used as a loading control. CRAF, Raf1 proto-oncogene, serin/threonine kinase;
MEK, Mitogen-activated protein kinase kinase 1; ERK, Extracellular regulated MAPKinase.
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Positive AM staining was completely abolished by pre-
absorption of the antibody with 50 mmol/L synthetic AM
peptide (see Fig. 5A).
To evaluate the functional role of AM in MPM
tumorigenesis, we investigated the effects of inhibition of
AM signaling on tumor xenografts. To assess the poten-
tial therapeutic value of aAM antibody and AM22–52,
athymic nude mice bearing established MSTO-211H tu-
mor xenografts (>200 mm3) were treated with aAM,
AM22–52, or a rabbit control IgG. Treatment was admin-
istered by IP injection every day for AM22–52 (50 mg/
mouse), as reported previously,31 and every 3 days foraAM antibody (12 mg/kg) and control IgG (12 mg/kg).
To monitor tumor growth, tumor volume was measured
throughout the treatment period. The growth of the
MSTO-211H xenografts was signiﬁcantly inhibited by
aAM and AM22–52 treatments compared with that in the
control group (Fig. 5B). After a 24-day treatment period,
a group of animals (n ¼ 5) was humanely killed, and
tumor size and vascularity were assessed. The mean
tumor weights in the animals treated with control IgG,
aAM antibody, and AM22–52 were 2.80 ± 0.40 g, 1.35 ±
0.25 g, and 1.55 ± 0.20 g, respectively, after 27 days of
treatment (Fig. 5C). Tumors from the animals treated
with aAM antibody and AM22–52 were pale and showed
Figure 5. Adrenomedullin (AM) signaling blockade inhibited the growth of MSTO-211H xenografts in vivo. (A) Immunohis-
tochemistry for immunoreactive AM in the MSTO-211H xenografts, brain, and kidney of nude mice. Strong staining was
observed in the xenograft specimens. In the brain and kidney, immunoreactive AM was undetectable. (B) MSTO-211H cells
(2  106) were injected subcutaneously into the ﬂanks of athymic nude mice (6 weeks old) (n ¼ 10 in each group). Mice with
tumor volumes averaging 200 to 300 mm3 received intraperitoneal injections of anti-AM (aAM) (12 mg/kg) every 3 days or
AM22–52 peptide (50 mg/mouse) daily. Control mice were treated with 12 mg/kg of nonspeciﬁc isotype control immunoglobulin
G (IgG). Tumor size was measured every 3 days, and signiﬁcant differences between the animals treated with aAM- and
AM22–52 and the animals treated with control IgG were determined by a one-way analysis of variance test (*p < 0.05;
**p < 0.01). (C) Tumors were weighed immediately after excision. The average tumor weight is indicated as the mean ±
standard error of the mean (n ¼ 10). (D) The photograph shows an example of tumors from the animals treated with aAM and
control IgG that were collected at the end of treatments. Note the pale character and the apparent diminished vasculature in
tumor from the aAM-treated animal when compared with tumor from control IgG–treated animals.
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extensive vascularization were observed in the control
groups (Fig. 5D).
AM blockade impairs tumor angiogenesis and
lymphangiogenesis and induces apoptosis
Histopathologic analysis revealed that large necrotic
areas were more prevalent in the tumors from animals
treated with aAM antibody and AM22–52 than in the
tumors from the animals treated with control IgG
(Fig. 6A). Immunohistochemical staining performed on
the tumor xenografts demonstrated no signiﬁcant differ-
ences in the Ki-67 labeling index between the animalstreated with aAM antibody, AM22–52, and control IgG
(Figs. 6A and 6B). Signiﬁcantly higher numbers of cleaved
caspase-3–positive cells were observed in tumors from
the animals treated with aAM antibody and AM22–52
(Fig. 6C). Consistentwith our hypothesis that AMsignaling
inhibition would result in a decrease in angiogenesis and
lymphangiogenesis, immunohistochemical staining for
the endothelial cell marker CD31 and the lymphatic
endothelial cell marker LYVE-1 demonstrated that
tumor vascularization is deeply disrupted in tumors from
animals treated with aAM antibody and AM22–52 (see
Fig. 6A). Quantiﬁcation of CD31-positive endothelial
cells and LYVE-1–positive lymphatic endothelial cells
Figure 6. Blockade of adrenomedullin (AM) signaling induces apoptosis and impairs angiogenesis and lymphangiogenesis in
malignant pleural mesothelioma tumor xenografts. (A) Representative images of tumors from the animals treated with
control immunoglobulin G, AM22–52, and anti-AM antibody. Tumor sections were stained with hematoxylin and eosin, Ki-67,
cleaved caspase-3, CD-31, and lymphatic vessel hyaluronic acid receptor-1 (LYVE-1) antibodies. Necrotic areas surrounding
the tumor tissue are clearly shown in the tumors treated with AM22–52 and anti-AM antibody. Cleaved caspase-3– and Ki-67–
positive cells are shown; they were analyzed on the basis of 10 magniﬁcation ﬁelds (400) per section. Immunohistochemical
staining of the endothelial cell surface marker CD31 was used to determined microvessel density. Quantitative assessment of
the density of cells that stained positive for Ki-67 (B), cleaved caspase-3 (C), CD-31 (D), or LYVE-1 (E) was conducted for the
entire surface of the corresponding slides using CALOPIX Software. MBF_Image J 1.43U software was used for the analysis.
The values shown represent the means ± standard error of the mean (*p < 0.05; **p < 0.01; ***p < 0.001; n.s.,
nonsigniﬁcant).
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from animals treated with aAM antibody and AM22–52
compared with the levels in control MSTO-211H tumors
(p < 0.1; p < 0.001; Figs. 6A, D, and E).
Discussion
The complex nature of MPM is reﬂected in the lack of
success of the current therapeutic strategies. Regardless
of the therapy, a dramatic difference in survival between
treated and untreated patients with MPM has not been
observed.37 Therefore, research aimed at deﬁning thegrowth mechanisms in MPM is imperative for identifying
relevant biological targets and designing new clinical
trials in an informed manner. In this study, we investi-
gated the expression of AM and its receptors in pleural
tumors from patients with MPM and the potential role
of AM as an autocrine/paracrine growth factor to pro-
mote growth of MPM in vitro and in vivo. Real-time
quantitative RT-PCR results revealed a signiﬁcant
increase in the expression of AM mRNA in MPM
samples compared with that in normal pleura. Moreover,
immunohistochemical analysis revealed that AM and AM
January 2016 Functional Analysis of AM Pathway in MPM 105receptors localize mainly to MPM cells. The expression of
AM and its receptors in MPM specimens strongly sug-
gests that AM could be involved in progression of MPM.
Our data demonstrate that hypoxic conditions induce
a severalfold increase in AM expression in MSTO-211H,
H2452, and H2052 cells. The increase in production
and secretion of bioactive AM in these cells under hypoxic
conditions suggests that a similar scenario may occur in
tissue neoplasms. The production and secretion of AM at
hypoxic areas present in tumors38,39 could establish an
autocrine/paracrine-mediated proliferation event lead-
ing to tumor growth. In addition, the angiogenic and
vasodilator capabilities of AM16,40 may be associated with
its ability to promote a stable and functional vascular
network and facilitate the nutritional supplementation of
tumor cells. Finally, AM protects cells from apoptosis,41
and this feature could selectively rescue tumor cells
from death, thereby resulting in the predisposition of
tumors toward a more malignant phenotype.38
The presence of AM, AMR1, and AMR2 in MPM tis-
sue suggests that AM may act as an autocrine/para-
crine growth factor in MPM tumors. Our data show
that AM signiﬁcantly increases proliferation and inva-
siveness in MSTO-211H and H2452 cells and increases
activation of the CRAF/MEK/ERK/MAPK pathway.
These data indicate that MPM cells respond to AM in a
manner that is consistent with an increase in the
aggressiveness of MPM. We demonstrated that aAM
and aAMR antibodies could inhibit the basal levels of
MPM cell proliferation and invasion in vitro, which is
consistent with the fact that AM can act in an autocrine
manner in MPM cells. The presence of an autocrine
loop suggests that the foci of AM-producing cells in
tumor tissue could stimulate cells expressing AM re-
ceptors through autocrine/paracrine mechanisms. Our
results suggesting that AM can act as an autocrine/
paracrine growth factor in MPM tissue are in agree-
ment with previously reported data on other forms of
cancer in which AM acts in a similar autocrine/para-
crine manner.11,12,15–19
The role of AM in the stimulation of tumor cell pro-
liferation, inhibition of apoptosis, and stabilization of
angiogenesis has been observed in several malig-
nancies,12,26,27,29 and these activities may be relevant in
the development of MPM. Our results demonstrate
that the blockade of AM signaling by aAM antibody or
AM antagonist peptide (AM22–52) signiﬁcantly decreases
the growth of established MSTO-211H tumor xenografts.
After 27 days of treatment, the tumors in mice treated
with control IgG grew rapidly to a size requiring hu-
mane killing of the animal, whereas the volume of the
tumors of the animals treated with aAM antibody or
AM22–52 remained signiﬁcantly lower than that of the
tumors of the animals treated with control IgG. Theimmunohistochemical analysis of tumors derived from
animals treated with aAM antibody or AM22–52 showed a
clear decrease in microvessel density, with an 80% to
90% reduction in endothelial cells within the tumor,
which is consistent with the role of AM in endothelial cell
survival and recruitment. In agreement with previous
studies, these data demonstrate that AM could induce
neovascularization and vessel stabilization.12,27,42
Recently, we showed that the blockade of AM signaling
selectively targets unstable tumor neovessels through
rapid disengagement of the VE-cadherin/b-catenin
complex, destabilization of the cytoskeleton organization
of endothelial cells, and subsequent apoptosis-mediated
cell death.43 Increased tumor vessel density appears to
negatively affect the survival of patients with MPM,44
and antiangiogenic targeted therapies could be useful
for MPM treatment.45 Of the antiangiogenic therapies,
bevacizumab, which is a humanized monoclonal anti-
body directed against vascular endothelial growth factor,
has been assessed in combination with ﬁrst-line
chemotherapy in numerous phase II clinical trials, and
the ﬁnal results of the randomized phase III trial Meso-
thelioma Avastin Plus Pemetrexin-Cisplatin Study
(NCT00651456) have recently demonstrated that the
triplet cisplatin–pemetrexed–bevacizumab signiﬁcantly
increases overall survival in patients with MPM.46
Because the vascular endothelial growth factor and AM
pathways are complementarily involved in tumor neo-
angiogenesis,47 targeting both pathways concomitantly
or sequentially might optimize the effects of either
antiangiogenic strategy in the treatment of MPM.
Like blood vessel angiogenesis, lymphangiogenesis
has attracted attention as an important initial step in
tumor pathogenesis.48,49 Intratumoral or peritumoral
lymphangiogenesis increases the risk for metastasis in
animal models and in human tumors.48 To determine
whether blockade of AM signaling in MSTO-211H xeno-
grafts could impair lymphatic vessel growth, we
analyzed the growth of lymphatic vessels within the
tumor tissue using a murine LYVE-1 antibody. LYVE-1–
positive lymphatic vessels were observed in the control
tumors and were signiﬁcantly decreased in the tumors
treated with AM22–52 or aAM antibody. These results
suggest that AM signaling induces the growth of
lymphatic vessels as a part of its protumorigenic func-
tions. These ﬁndings are in agreement with recent data
suggesting that tumor-secreted AM is a critical factor in
driving tumor lymphangiogenesis.28,30 Recently, we
demonstrated that activation of AM receptors by AM
induces proliferation, migration, invasion, and survival of
lymphatic endothelial cells (LECs), thus suggesting an
important role for AM in establishing functional
lymphatic vessels during tumor growth.28 In this context,
the current study provides evidence suggesting that the
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through upregulated AM expression12,28,33 may be
important not only for supporting tumor growth and
neoangiogenesis but also for promoting tumor lym-
phangiogenesis. Thus, targeting the AM system or
pharmacologically targeting AM signaling may provide a
new avenue for the inhibition of both tumor angiogen-
esis and lymphangiogenesis.
In conclusion, our ﬁndings suggest that the AM sys-
tem is a relevant target for treatment of MPM and thus
warrants additional preclinical and clinical research into
its effects on the development of MPM.
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